The goals of the Biomarker Core, directed by John Trojanowski, M.D. and co-directed by Leslie Shaw, Ph.D. at the University of Pennsylvania, are to establish a bank of biological fluids from the unique cohort of subjects followed in ADNI and conduct studies of selected AD biomarkers:
- APOE genotyping of all new study subjects
- CSF Aβ and tau (partner with Innogenetics to assay all measurable species) CSF and plasma isoprostanes (all measurable species)
- CSF and plasma homocysteine
- Plasma Aβ (partner with Innogeneticsto assay all measurable species)
- Implement/validate promising new biomarkers such as BACE, and other species of tau and Aβin CSF, but especially in plasma
- Proteomic Analysis
- Biomarker Core News
- CSF Biomaker Qualification Study Test Instructions
- Biomarker Core Progress Report 2008
- Practical Neurology – December 2004
|John Q. Trojanowski, M.D., Ph.D.
University of Pennsylvania
John Trojanowski’s research focuses on the role of protein misfolding in neurodegeneration, which is a core disease mechanism shared by Alzheimer’s (AD), Parkinson’s (PD) and related disorders. Since early diagnosis of AD is critical to developing effective AD therapies, Dr. Trojanowski exploits insights into disease mechanisms to develop and validate relevant and informative AD biomarkers.